Twinbeech Capital LP Has $14.56 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Twinbeech Capital LP reduced its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 27.4% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 74,101 shares of the medical research company's stock after selling 27,962 shares during the period. Twinbeech Capital LP's holdings in IQVIA were worth $14,562,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Smith Group Asset Management LLC acquired a new stake in shares of IQVIA during the fourth quarter worth $1,616,000. Hickory Asset Management Inc. acquired a new stake in shares of IQVIA during the fourth quarter worth $941,000. Fifth Third Bancorp grew its stake in shares of IQVIA by 13.0% during the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock worth $2,590,000 after purchasing an additional 1,521 shares during the period. Graphene Investments SAS grew its stake in shares of IQVIA by 22.0% during the fourth quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock worth $2,948,000 after purchasing an additional 2,700 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after purchasing an additional 583,396 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

IQV opened at $143.32 on Tuesday. IQVIA Holdings Inc. has a 52-week low of $135.97 and a 52-week high of $252.88. The firm has a market capitalization of $24.79 billion, a PE ratio of 19.11, a PEG ratio of 1.99 and a beta of 1.34. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The business's 50-day simple moving average is $158.99 and its 200 day simple moving average is $185.26.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The business had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. During the same quarter in the prior year, the company posted $2.54 earnings per share. IQVIA's revenue was up 2.5% on a year-over-year basis. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on IQV. Mizuho decreased their target price on IQVIA from $210.00 to $190.00 and set an "outperform" rating for the company in a research note on Thursday, May 15th. Citigroup decreased their target price on IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Truist Financial decreased their target price on IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research note on Thursday, April 10th. Stifel Nicolaus decreased their target price on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Finally, BTIG Research cut IQVIA from a "buy" rating to a "neutral" rating in a research note on Monday, February 3rd. Eight analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $228.14.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.